Filing search / 1993+ / Entero Therapeutics, Inc. / Page 24

4

yl2 mh71f

19 Feb 19

AzurRx BioPharma / Edmund Burke Jr. Ross ownership change

9:45pm

SC 13G/A

bzxm4cw7qab7fqgswb

14 Feb 19

AzurRx BioPharma, Inc.

11:23am

SC 13G/A

gqx9des

13 Feb 19

AzurRx BioPharma, Inc.

4:42pm

SC 13G/A

ovp2wex sdv0knd3

29 Jan 19

AzurRx BioPharma, Inc.

3:44pm

SC 13D/A

4j0gznjqfet uo

8 Jan 19

AzurRx BioPharma, Inc.

12:00am

4

q1bx bpidmbnvsa67b8

7 Jan 19

AzurRx BioPharma / Edmund Burke Jr. Ross ownership change

6:49pm

4

4c3o gpbwx0

2 Jan 19

AzurRx BioPharma / Johan M. Spoor ownership change

6:47pm

4

385r xf63j

2 Jan 19

AzurRx BioPharma / Maged Shenouda ownership change

6:44pm

4

eurfb2x13t2

2 Jan 19

AzurRx BioPharma / EDWARD BORKOWSKI ownership change

6:03pm

4

92vudcfmj 0bxw

2 Jan 19

AzurRx BioPharma / Vern Lee Schramm ownership change

6:01pm

4

pzz7o

2 Jan 19

AzurRx BioPharma / CHARLES J CASAMENTO ownership change

5:58pm

4

ppw57q cshiv0e

2 Jan 19

AzurRx BioPharma / Alastair Riddell ownership change

5:55pm

8-K

5zu8mz

20 Dec 18

AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients

5:07pm

8-K

3h920pn

13 Dec 18

AzurRx BioPharma to Acquire Payment Rights to Lead

4:39pm

8-K

t7t7r

5 Dec 18

AzurRx BioPharma to Present at Upcoming Investor Conferences

12:00am

8-K

m814zpc

8 Nov 18

Regulation FD Disclosure

1:46pm

8-K

n2vvgz4w5oqu53

1 Nov 18

AzurRx BioPharma Receives Sanction of Cystic Fibrosis  Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI

3:27pm

8-K

hnpu9cd 9bu2wy2n2sx

22 Oct 18

On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019

4:07pm

8-K

4zmbpmi9twg

2 Oct 18

Regulation FD Disclosure

12:00am